Eyeworld

NOV 2014

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/407647

Contents of this Issue

Navigation

Page 5 of 90

3 EW NEWS & OPINION ASCRS responds to FDA PROWL studies November 2014 P reliminary results of the Food and Drug Administration/National Eye Institute/Department of Defense LASIK Quality of Life Project were released during the 2014 American Academy of Ophthalmology (AAO) annual meeting. The multi-year study, which utilized the Patient Reported Outcomes with LASIK (PROWL) questionnaire, examined patient- reported outcomes (PROs) following LASIK. Two versions of the PROWL study were conducted: military (PROWL-1; 262 subjects) and non-military (PROWL-2; 312 subjects). The results are overwhelm- ingly positive and confirm the results of many other studies: More than 96% of subjects report being satisfied with their vision at 3 months following LASIK. "In the 25 years since the FDA commenced their first excimer laser trial in 1989 for refractive keratecto- my, LASIK has been shown in hundreds of clinical studies as a very safe and effective procedure for low to moderate levels of refrac- tive error," said ASCRS President Richard A. Lewis, MD. "The high rate of success is unprecedented as a surgical procedure. The collaborative work between military and non-mil- itary ophthalmologists in conjunc- tion with the FDA in the PROWL-1 and PROWL-2 studies confirm the remarkable efficacy of LASIK. Our understanding of those at risk for dry eyes and visual disturbances from LASIK procedures is critical and evolving. The questionnaires developed in the PROWL studies will help identify those at risk. The ques- tionnaires, however, must be used in studies as compared to a control group such as contact lens wearers, etc. Furthermore, a 3-month study is insufficient as the vast majority of these symptoms resolve with time. Identifying individuals at high risk for complications of LASIK is valuable. However, this must be determined in a well-controlled and timely trial." The following summary was written by Ed Manche, MD, Eric Donnenfeld, MD, Doyle Stulting, MD, Kerry Solomon, MD, John Vukich, MD, and Daniel Durrie, MD, and outlines the FDA's findings further. The facts about the FDA PROWL studies The PROWL-1 study, completed in 2014 with 262 participants, was conducted at the U.S. Naval Medical Center San Diego, using a question- naire to determine patient-reported outcomes (PRO) in a patient popula- tion undergoing standardized treat- ment. The intent behind PROWL-1 was to develop a questionnaire to better evaluate patients' reporting of visual symptoms and to assess the potential of those symptoms to impact a patient's quality of life after LASIK. The PROWL-2 study, also completed in 2014 with 312 participants, was designed to further validate the questionnaire in a national, multicenter clinical study of a civilian population. The FDA presented preliminary findings from both the PROWL-1 (6-month data) and PROWL-2 (3-month data) studies during the 2014 AAO annual meeting. With the studies completed and analyses un- derway, PROWL is the first prospec- tive study to evaluate the multiple aspects of a patient's experience with LASIK, including expectations, satisfaction, visual symptoms and their impact on daily life. The preliminary findings confirm high patient satisfaction rates and provide more context to visual symptoms reported, such as ghost- ing, halos, starburst, and glare, along with dry eye, both preop and postop. As these findings are further analyzed, they will allow us, as physicians, to further enhance our discussions with patients about benefits and risks of LASIK surgery. A very small set of the data collect- ed has been analyzed, and we look forward to additional findings and analysis. While the FDA is obligated to look at the public health impact of these findings, it is the responsi- bility of the medical community to not only establish a foundation of unbiased scientific evidence about LASIK patient satisfaction, but also address that small percentage of dissatisfied patients and learn everything we can to improve LASIK satisfaction rates. We remain firm in our commitment to the ongoing work. For more than a decade, LASIK—one of the most studied medical procedures—has been con- sidered a safe and effective vision correction option for those who are nearsighted, farsighted, and/or have astigmatism. Millions of people have benefitted from LASIK. LASIK is surgery, and no surgery is 100% risk free. The PROWL findings: What you need to know • Common findings in PROWL-1 and PROWL-2 trials › Only 1 of 990 eyes lost 3 or more lines of visual acuity, and that eye saw 20/25 or better. › The prevalence of all visual symptoms and bothersome symptoms studied (ghosting, halos, glare, and starbursts) was less at 6 months after surgery without correction than it was preoperatively with best correction (PROWL-1). › Patients reporting difficulty or the inability to perform usual activities due to visual symp- toms improved or were com- pletely eliminated following LASIK in both studies. › Visual symptoms throughout these trials must be understood in the context that there was no correction of residual refrac- tive error. While the results are excellent, they would be even better if patients had been given the option to have additional LASIK or to wear glasses. • PROWL-1 summary (6 months) › 99% of patients had a binocular uncorrected vision of 20/20 or better at 3 months. › When asked how satisfied patients were with the results of their LASIK surgery, 98% report- ed being satisfied at 6 months and 2% were dissatisfied. › When asked "How satisfied are you with present vision?" 97% were satisfied at 6 months and 3% were dissatisfied. This is a significant improvement, since 73% were dissatisfied preop. › For each symptom index, up to 30% of patients reported new visual symptoms, while 91% of patients reported the resolution of symptoms they had prior to LASIK. Thus, 3 times more patients reported the resolution of preop visual symptoms than reported new visual symptoms. › Very few patients reported that visual symptoms negatively impacted their daily activities. › 21% (23 subjects) with a normal preop Ocular Surface Disease Index (OSDI) noted mild, moderate, or severe dry eye at 6 months. 65% of patients with preop mild, moderate, or severe dry eye symptoms had normal OSDI scores at 3 months. Thus, 3 times more patients experi- enced an improvement in OSDI after LASIK than noticed new OSDI symptoms. Subjects were not followed long enough to observe the resolution of the dry eye symptoms, which was re- ported to occur in the literature. • PROWL-2 summary (3 months) › 96% of patients had binocular uncorrected vision of 20/20 or better at 3 months. › 97% were satisfied with their LASIK surgery at 3 months. › 96.2% were satisfied with their vision at 3 months, while 3.9% were dissatisfied. This is an improvement since 55.9% were dissatisfied preoperatively. › Up to 1% of subjects, without glasses or contact lenses, experi- enced a lot of difficulty with or were unable to do usual activi- ties due to visual symptoms at 3 months. The ability of glasses or contact lenses to correct visual symptoms was not presented. › The prevalence of halos decreased from 51% (preoper- atively) to 46% (at 3 months) in all patients following LASIK. continued on page 8

Articles in this issue

Archives of this issue

view archives of Eyeworld - NOV 2014